VILLA DURAZZO PALLAVICINI – FRIDAY 6 SEPTEMBER

17.30

Management of acquired Haemophilia A: A case series
S. Varvello (Italy)
VIEW ePOSTER

17.40

Immune Tolerance Induction with Nuwiq® (Simoctocog Alfa) in Nine Patients with Severe Haemophilia A and Inhibitors to FVIII
R.J. Liesner (UK)
VIEW ePOSTER

17.50

Final results from the NuProtect study of Nuwiq® (simoctocog alfa) treatment in previously untreated patients with severe haemophilia A
R.J. Liesner (UK)
VIEW ePOSTER

18.00

Combination of emicizumab with simoctocog alfa for prophylaxis in previously untreated/minimally treated hemophilia A patients, and for managing inhibitor patients
R. Sidonio (USA)
VIEW ePOSTER

18.10

Population pharmacokinetic model for recombinant factor VIII Fc fusion protein (rFVIIIFc) validated and optimized for use in children
L.H. Bukkems (The Netherlands)
VIEW ePOSTER

18.20

The combination of plasma-derived FVIII/VWF with emicizumab has non-additive effects on thrombin generation assay independently of the presence of inhibitors in hemophilia A plasma
A. Perez (Spain)
VIEW ePOSTER

VILLA DURAZZO PALLAVICINI – SATURDAY 7 SEPTEMBER

18.30

Prognostic value of polymorphisms of the CYP2C19 gene in the development of stent thrombosis
A. Zhunuspekova (Croatia)
VIEW ePOSTER

18.40

Six years of experience with plasma fractionation industries at a private super speciality hospital in South India: renaissance in usage of excess plasma in blood banks
B. Poluru Mranikrinda (India)
VIEW ePOSTER

18.50

Evaluation of the chromogenic assay “Biophen factor IX” on Sysmex CS-2400 analyzer
C. Novembrino (Italy)
VIEW ePOSTER

19.00

Testing clot growth and thrombin wave patterns in haemophilia patients
C. Kluft (The Netherlands)
VIEW ePOSTER

19.10

Overview of efficacy and safety of a plasma-derived human von Willebrand factor concentrate for perioperative management and delivery in patients with hereditary VWF deficiency, unresponsive to dDAVP
F. Bridey (France)
VIEW ePOSTER